C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy

BJU International

Volumn 101, Issue 8, 2008, Pages 978-981

  Yoshida, Soichiro ^a   Saito, Kazutaka ^a   Koga, Fumitaka ^a   Yokoyama, Minato ^a   Kageyama, Yukio ^a   Masuda, Hitoshi ^a   Kobayashi, Tsuyoshi ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Biological marker; Bladder cancer; C reactive protein; Inflammatory reaction; Prognosis; Radiotherapy

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFLAMMATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CISPLATIN; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 41049106719     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07408.x     Document Type: Article

References (17)

1. Kakizoe T, Yamaguchi N, Mitsuhashi F, Koshiji M, Oshima A, Ohtaka M. Cancer Statistics in Japan - 2001. Tokyo : Foundation for Promotion of Cancer Research, 2001 : 38
2. Tsukamoto T, Kitamura H, Takahashi A, Masumori N. Treatment of invasive bladder cancer: lessons from the past and perspective for the future. Jpn J Clin Oncol 2004 34 : 295 306
3. Kageyama Y, Yokoyama M, Sakai Y et al. Favorable outcome of preoperative low dose chemoradiotherapy against muscle-invasive bladder cancer. Am J Clin Oncol 2003 26 : 504 7
4. Quek ML, Quinn DI, Daneshmad S, Stein JP. Molecular prognostication in bladder cancer - a current perspective. Eur J Cancer 2003 39 : 1501 10
5. Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 2000 91 : 416 23
6. Miyata Y, Kanda S, Ohba K et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A-C, and - D. Clin Cancer Res 2006 12 : 800 6
7. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003 90 : 215 9
8. Heys SD, Ogston KN, Simpson WG et al. Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int J Oncol 1998 13 : 589 94
9. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 2005 18 : 146 50
10. Saito K, Kawakami S, Ohtsuka Y et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007 100 : 269 73
11. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007 99 : 77 80
12. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 2005 92 : 625 7
13. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours, 5th edn. New Jersey : Wiley-Liss Inc, 1997
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998 22 : 1435 48
15. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997 72 : 149 54
16. Eustace D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol 1993 50 : 15 9
17. Miki S, Iwano M, Miki Y et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989 250 : 607 10